Assess whether scientific advice should be sought before the next trial

Situation

A competitor label that just got a narrower indication put advisory-committee question list that exposes a weak secondary endpoint in front of pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Clinical and Evidence Strategy close is scientific advice should be from advisory-committee question list that exposes a weak secondary endpoint, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using advisory-committee question list that exposes a weak secondary endpoint after a competitor label that just got a narrower indication.

Hypotheses to test

• A competitor label that just got a narrower indication is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given advisory-committee question list that exposes a weak secondary endpoint.
• A competitor label that just got a narrower indication is the event in advisory-committee question list that exposes a weak secondary endpoint that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences.
• Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after a competitor label that just got a narrower indication, not a Clinical and Evidence Strategy program failure.
• Advisory-committee question list that exposes a weak secondary endpoint cannot decide scientific advice should be yet after a competitor label that just got a narrower indication; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pediatric-plan strategist would keep.
• Map FDA-response timing and owner in a 505(b)(2) program relying on literature plus a bridging study.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read advisory-committee question list that exposes a weak secondary endpoint against a competitor label that just got a narrower indication and write the one fact that would move scientific advice should be for pediatric-plan strategist.